NASDAQ Healthcare Biotechnology PBLS

Parabilis Medicines, Inc.

$ 25.85 -0.69 %

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

CEO: Mathai Mammen - http://www.parabilismed.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -

Loading data...

PBLS vs S&P500

Loading data...

No data available.

Quick ratio

0

P/E ratio

-14.60

may indicate that the company is undervalued or has poor growth prospects.

EPS

-1.77

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

0 %

ROIC

0 %

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-

Free cash flow per share

0

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0 %

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
N/A
Altman score
N/A
Loading data...

No data available.

Cash / Debt

Cash Ratio
Debt Ratio
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.